Controlled transdermal delivery of leuprorelin by pulsed iontophoresis and ion-exchange fiber.

[1]  Maelíosa T. C. McCrudden,et al.  Strategies for enhanced peptide and protein delivery. , 2013, Therapeutic delivery.

[2]  K. Kontturi,et al.  Ion-exchange and iontophoresis-controlled delivery of apomorphine. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  G. Ponchel,et al.  Leuprolide acetate: pharmaceutical use and delivery potentials , 2012, Expert opinion on drug delivery.

[4]  Y. Kalia,et al.  Non-invasive iontophoretic delivery of peptides and proteins across the skin , 2011, Expert opinion on drug delivery.

[5]  A. Banga,et al.  Transdermal Delivery of Peptides and Proteins , 2011 .

[6]  C. Atwood,et al.  Leuprolide acetate: a drug of diverse clinical applications , 2007, Expert opinion on investigational drugs.

[7]  Y. Kalia,et al.  Effect of amino acid sequence on transdermal iontophoretic peptide delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  Y. Kalia,et al.  Transdermal Iontophoretic Delivery of Vapreotide Acetate AcrossPorcine Skin in Vitro , 2005, Pharmaceutical Research.

[9]  B. Finnin,et al.  The transdermal revolution. , 2004, Drug discovery today.

[10]  G. Imanidis,et al.  In vitro transdermal iontophoretic delivery of leuprolide under constant current application. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Aarti Naik,et al.  Iontophoretic drug delivery. , 2004, Advanced drug delivery reviews.

[12]  R. Kostiainen,et al.  Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  F. Tse,et al.  Effect of Current Magnitude and Drug Concentration on lontophoretic Delivery of Octreotide Acetate (Sandostatin®) in the Rabbit , 1994, Pharmaceutical Research.

[14]  J. Li,et al.  Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: Preliminary report , 1992, Cardiovascular Drugs and Therapy.

[15]  G. Imanidis,et al.  In vitro transdermal iontophoretic delivery of leuprolide-mechanisms under constant voltage application. , 2003, Journal of pharmaceutical sciences.

[16]  E. Mini,et al.  Clinical Pharmacokinetics of Depot Leuprorelin , 2002, Clinical pharmacokinetics.

[17]  R H Guy,et al.  Characterization of the iontophoretic permselectivity properties of human and pig skin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[18]  J. Manzanares,et al.  Ion-exchange fibers and drugs: an equilibrium study. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Y. Kalia,et al.  Iontophoresis: electrorepulsion and electroosmosis. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[20]  P. Paronen,et al.  Transport of drugs across porous ion exchange membranes. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Y. Kalia,et al.  Transdermal delivery of peptides by iontophoresis , 1996, Nature Biotechnology.

[22]  P. G. Green.  Iontophoretic delivery of peptide drugs , 1996 .

[23]  R. Guy,et al.  Iontophoresis of nafarelin: Effects of current density and concentration on electrotransport in vitro , 1995 .

[24]  R. Guy,et al.  Iontophoretic delivery of nafarelin across the skin , 1995 .

[25]  H. Merkle,et al.  Dermal metabolism of topically applied drugs: pathways and models reconsidered. , 1995, Pharmaceutica acta Helvetiae.

[26]  W. Higuchi,et al.  Iontophoretic enhancement of peptides: behaviour of leuprolide versus model permeants , 1994 .

[27]  F. Puisieux,et al.  Preservation of skin permeability during in vitro iontophoretic experiments , 1994 .

[28]  F. Moll,et al.  In vitro pulsatile and continuous transdermal delivery of buserelin by iontophoresis , 1993 .

[29]  H. Hui,et al.  The Effects of Formulation Variables on Iontophoretic Transdermal Delivery of Leuprolide to Humans , 1993 .

[30]  R. Guy,et al.  Rate control in transdermal drug delivery , 1992 .

[31]  L. Miller,et al.  Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues. , 1990, Journal of pharmaceutical sciences.

[32]  W. Shi,et al.  Direct current iontophoretic transdermal delivery of peptide and protein drugs. , 1989, Journal of pharmaceutical sciences.

[33]  W. Kreis,et al.  Successful transdermal administration of therapeutic doses of a polypeptide to normal human volunteers , 1988, Clinical pharmacology and therapeutics.

[34]  H. Yamaguchi,et al.  New iontophoretic transdermal administration of the beta-blocker metoprolol , 1986 .

[35]  L. Sennello,et al.  Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. , 1986, Journal of pharmaceutical sciences.

[36]  M J DAVIS,et al.  Electrical characteristics of the skin. The impedance of the surface sheath and deep tissues. , 1960, The Journal of investigative dermatology.